Sprint Bioscience AB publ announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was SEK 408,000 compared to SEK 5.517 million a year ago. Operating loss was SEK 13.034 million compared to SEK 9.487 million a year ago. Net loss was SEK 13.695 million compared to SEK 9.765 million a year ago. Basic loss per share from continuing operations was SEK 0.64 compared to SEK 0.79 a year ago.